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β-thalassemia encompasses a group of monogenic diseases that have in common defective synthesis of β-globin. The defects
involved are extremely heterogeneous and give rise to a large phenotypic spectrum, with patients that are almost asymptomatic to
cases in which regular blood transfusions are required to sustain life. As a result of the ineﬃcient synthesis of β-globin, the patients
suﬀer from chronic anemia due to a process called ineﬀective erythropoiesis (IE). The sequelae of IE lead to extramedullary
hematopoiesis (EMH) with massive splenomegaly and dramatic iron overload, which in turn is responsible for many of the
secondarypathologiesobservedinthalassemicpatients.Theprocessesareintimatelylinkedsuchthatanidealtherapeuticapproach
should address all of the complications. Although β-thalassemia is one of the ﬁrst monogenic diseases to be described and
represents a global health problem, only recently has the scientiﬁc community started to focus on the real molecular mechanisms
that underlie this disease, opening new and exciting therapeutic perspectives for thalassemic patients worldwide.
1.Introduction
The biochemical signature of β-thalassemia is a reduced
synthesis of the β-globin subunit of HbA (α2β2). Individuals
inheriting two β-thalassemic alleles experience a profound
deﬁcit in β-chain production, and this impairment leads to
excess production of α-globin. No compensatory regulatory
mechanism exists where impaired synthesis of β-globin
subunit leads to an excess production of the α-globin.
Therefore, in β-thalassemia, the excess α-globin chains form
tetramers that accumulate and precipitate in the erythroid
progenitors, forming inclusion bodies that cause oxidative
membrane damage within the red blood cells and immature
developing erythroblasts in the bone marrow. This leads to
premature death of many late erythroid progenitors in the
bone marrow and spleen (Hoﬀman et al., Hematology, Basic
Principles and Practice). The profound anemia that results
from production of only a few hypochromic and microcytic
red blood cells leads to a dramatic increase in erythropoietin
(EPO) levels, that ultimately drive an uncontrolled expan-
sion of additional early erythroid progenitors inducing mas-
sive EMH. These erythroid progenitors have an enhanced
proliferative and survival capacity, but eventually they fail
to diﬀerentiate, contributing to the process of IE [1]. The
standard treatment for thalassemic patients is chronic blood
transfusion to ameliorate the hemoglobin level. Chronic
transfusion therapy is required to sustain life in patients with
β-thalassemia major and often becomes necessary in those
with β-thalassemia intermedia who develop splenomegaly.
T h em a i ns i d ee ﬀect of transfusion therapy is the dramatic
iron overload. Secondary iron overload is indeed one of the
major causes of morbidity in thalassemic patients. Excessive
iron in the circulation leads to abnormal accumulation in
organs such as liver, spleen and heart, leading ultimately
to liver disease, cardiac dysfunction, arthropathy, gonadal
insuﬃciency, and other endocrine disorders (Hoﬀman et al.,
Hematology, Basic Principles and Practice). β-thalassemia
is also an iron loading anemia, meaning that thalassemic
patients have a dramatic increase in iron absorption from
the gut due to their increased erythropoietic rate. This
increased iron absorption is mainly mediated by down-
regulation of the ironregulatory hormone hepcidin [2–9],
and together with the iron inﬂux from chronic transfusions
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in thalassemic patients. Current treatment for iron overload
includes administration of iron chelators like desferoxamine,
deferasirox, and deferiprone [10] .T h o s ea g e n t sd e c r e a s et h e
iron burden in the liver and heart, signiﬁcantly increasing
thelifespanofthalassemicpatients.Splenectomyisalsooften
necessary to contain the iron burden when the transfusion
requirement becomes excessive (β-thalassemia major) or the
anemia worsens (β-thalassemia intermedia). Splenectomy,
however, introduces a new set of problems. Splenectomized
patients have an increased risk of infections, of developing
thrombotic events, and of pulmonary hypertension, all life-
threateningconditions[11–14].Theseobservationssuggesta
reconsideration of splenectomy in thalassemic patients. The
use of agents able to reduce the spleen size thereby allowing
patients to avoid splenectomy could be an eﬃcient option
in those who develop splenomegaly. All of the approaches
described above target secondary pathologies that result
from IE in β-thalassemia. Therefore, treatment of IE itself
could ameliorate all secondary pathologies that stem from it.
2.Jak2 andErythropoiesis
During the erythropoietic process, multipotent stem cells
in the bone marrow divide and diﬀerentiate giving rise to
approximately 2 million nonnucleated reticulocytes every
second. This process is tightly regulated by an array of events
that include cytokine signaling and cell-cell interactions,
mainly in the context of erythroblastic islands, a specialized
niche for the maturation of erythroid progenitors [15].
Since the pivotal role of erythrocytes is carrying oxygen to
tissues, the erythropoietic process must be able to respond
quickly and eﬀectively to changes in tissue oxygen tension.
This is accomplished mainly by erythropoietin (EPO). EPO
serves as the master regulator of erythropoiesis [16]. It
signals through the erythropoietin receptor (EPOR) and
controls virtually all stages of erythroid diﬀerentiation, from
committed common myeloid progenitors to the survival,
proliferation, and maturation of more late-stage erythroid
progenitors such as proerythroblasts and basophilic ery-
throblasts [17]. EPO exerts its eﬀects by binding to EPOR,
thereby activating the cytoplasmatic kinase Jak2. Activation
of Jak2 involves auto and crossphosphorylation events that
ultimately lead to activation of the signal transductor
and activator of transcription Stat5 a and b and parallel
signaling pathways [18]. Once activated, Stat5 migrates to
the nucleus and activates genes crucial for proliferation,
diﬀerentiation, and survival of erythroid progenitors. The
crucial importance of the EPO-EPOR-JAK2-STAT5 axis has
beendemonstratedbyknockoutstudiesinmicethatshowed
how lack of each one of these four molecules results in a
lethal phenotype (death due to severe anemia) during fetal
development [19]. The binding of EPO to EPOR leads to
activation of another important signaling pathway during
erythropoiesis: the phosphoinositol-3-kinase (PI3K)—AKT
pathway [20]. Studies in an apoptosis-resistant erythroid
cell line indicate that activation of PI3K is necessary but
not suﬃcient to protect against apoptosis [21]. Moreover,
mice that do not express the p85 α subunit of PI3K have
dramatically reduced erythropoiesis with reductions in the
numbers of CFU-E and BFU-E progenitors [22]. AKT, which
is the activated downstream of PI3K, transduces signals that
are necessary for the diﬀerentiation of erythroid progenitors
[23] and is important in regulation of the activity of the
FOXO3 transcription factor. The activity of FoxO3 is pivotal
in the regulation of oxidative stress during erythropoiesis,
as knockout mice exhibit a greater susceptibility to ROS-
induced oxidative stress [24]. The absence of FoxO3 was
associatedwithreductioninerythrocytelifespanaswellasan
enhancedmitoticarrestinintermediateerythroidprogenitor
cells, resulting in a decreased rate of erythroid maturation.
FoxO3-null erythrocytes also showed decreased expression
of ROS scavenging enzymes and evidence of oxidative dam-
age. Jak2 is a member of the Jak tyrosine kinase family, and
mediates the action of many other cytokines besides EPO.
Some examples include growth hormone, prolactin, TPO,
GM-CSF, interleukin 3, and interleukin 5. What makes the
associationbetweenEPOandJak2uniqueisthefactthatJak2
is the only kinase that is associated with EPOR and therefore
the only signal transductor of EPO. This important task is
accomplishedbyacomplex3Dstructurethatinvolveskinase,
pseudokinase, and regulatory domains. The 3D structure
allows for a ﬁnely tuned regulation of its activity, from its
association with EPOR to its phosphorylation and activation
[25].Whenregulationfails,theconsequencesaredeleterious.
In 2005, ﬁve diﬀerent research teams [26–30]d e s c r i b e da n
activating mutation (V617F) in the pseudokinase domain of
Jak2 that is associated with ≥90% of cases of polycythemia
vera and ∼50% of cases of essential thrombocythemia and
chronicidiopathicmyeloﬁbrosis.Inallofthesestudies,itwas
clear how hyperactivation of Jak2 contributes to a massive
increase in the erythropoietic activity and a huge expansion
of the erythron with related splenomegaly, a phenotype that
is interestingly similar to what is observed in β-thalassemia.
2.1. Jak2, Ineﬀective Erythropoiesis and Splenomegaly in β-
Thalassemia. In β-thalassemia, the erythropoietic process is
markedly altered and is referred to as ineﬀective erythro-
poiesis (IE). According to the traditional model, the lack or
reduced synthesis of β-globin during IE induces the forma-
tion of α-globin aggregates in erythroid progenitors. These
aggregates precipitate and adhere to the membrane causing
cellular damage, massive apoptosis of erythroid progenitors
in the bone marrow, and only limited production of red
blood cells which are abnormal. These abnormal/damaged
RBC are readily captured by the reticuloendothelial system
in the spleen and contribute to the splenomegaly observed
in thalassemic patients. The hypoxia arising from the lack
of production of normal RBC induces a dramatic increase
in the levels of EPO, which in turn induces a bone marrow
hyperplasia and bone deformities. This traditional view has
mainly focused on the apoptotic aspect of IE [31–33], which
is an important but not the only aspect of this process.
Recent studies using both mouse models of β-thalassemia
and specimens from thalassemic patients showed that,
together with apoptosis, a signiﬁcant number of erythroid
progenitors undergo increased proliferation and decreased
diﬀerentiation in the spleen [1]. In this model, high levelsAdvances in Hematology 3
of EPO act as the driving force for the survival and prolif-
eration of erythroid progenitors, albeit they fail to eﬃciently
diﬀerentiate giving rise to only a few RBCs. This process has
beenshowntobeassociatedwiththephosphorylatedformof
Jak2, leading to a higher number of proliferating thalassemic
erythroid progenitors compared to normal conditions, in
a sort of “physiological” gain of function (Figure 1). The
persistent phosphorylation of Jak2 as a consequence of high
EPO levels induces a massive extramedullary hematopoiesis
(EMH), with early erythroid progenitors colonizing then
proliferating mainly in the spleen and liver. In this scenario,
the spleen becomes a secondary erythropoietic niche, with
its enlargement (splenomegaly) being due mainly to the
colonization and proliferation of erythroid progenitors from
the bone marrow. In our study, we showed that erythroid
progenitors derived from the blood of thalassemic patients
express higher levels of cell cyclerelated mRNAs such as
J a k 2 ,K i 6 7 ,C y cA ,B c l X L ,a n dE p o R ,a n dt h a tt h e r ea r e
a considerable number of erythroid progenitors in the
spleen of thalassemic patients that are actively proliferating.
Moreover, recent studies have shown that, at least in the
mouse, there are erythroid progenitors that develop in
the spleen, with diﬀerent capacities for proliferation and
diﬀerentiation than the ones found in the bone marrow.
These erythroid progenitors display a higher sensitivity to
EPO and are selectively responsive to BMP4. They show
an improved capacity to respond to acute anemia and a
higher diﬀerentiation rate compared to their counterparts
in the bone marrow [34]. Another important study shows
how the transcription factor ID1 is directly upregulated by
the Jak2-Stat5 pathway in erythroid cells [35]. Since high
levels of ID1 have been found to inhibit cell diﬀerentiation,
its up-regulation due to a sustained activation of Jak2
by EPO in β-thalassemia could explain the less mature
erythroid progenitors observed. These ﬁndings shed light
on the mechanisms that underlie splenomegaly and raise
the intriguing question of whether there is also a basal
physiological level of erythropoietic activity in the human
spleen that is dramatically increased in stress conditions
such as IE. Although these observations have been demon-
strated in mouse models, further evaluation is necessary
in humans, especially considering the diﬀerences observed
in the erythropoiesis in the spleen comparing these two
species. Other mechanisms could be involved in the onset
of splenomegaly, like hepatic and portal vein obstruction,
cirrhosis or congestive heart failure that often appear in
thalassemicpatients.Alltheseconditionsleadtoanincreased
blood ﬂow to the spleen that in turn could be responsible for
the enlargement observed.
2.2. Possible Role of Jak2 Inhibitors in β-Thalassemia. The
discovery of Jak2 as an important mediator of IE and
splenomegaly in β-thalassemia suggests that the use of small
organic molecules to inhibit Jak2 could be beneﬁcial in
reducing IE and splenomegaly. The idea of treating an
erythropoietic disorder with an agent that limits erythro-
poiesis appears counterintuitive. However, the rationale for
its use is related to the fact that IE in β-thalassemia resem-
bles a leukemic blast expansion, with immature erythroid
progenitors that proliferate abnormally, fail to diﬀerentiate,
and invade other organs to compromise their function [1].
It is important to state that this is still a model that needs
further conﬁrmation, since mouse models of β-thalassemia
and leukemia have not been compared yet. Ideally, use of
a Jak2 inhibitor would target only the rapidly proliferat-
ing erythroid progenitors in the spleen (CD71+ Ter119+
early erythroid progenitors), blocking their expansion and
therefore allowing shrinkage of this organ by decreasing the
presence of red pulp. This in turn would contribute to an
improvement of the spleen architecture and a reduction of
RBC sequestration, enhancing their lifespan. Jak2 inhibitors
are indeed able to induce a dramatic decrease in spleen size
[1] in thalassemic animals with a limited eﬀect on anemia.
The drug would need to be carefully titrated in order to
achieve an optimal plasma concentration that would allow
the inhibition of excessive proliferation or early progenitors
without blocking erythropoiesis, as it would be expected
by completely inhibiting Jak2 [19]. This titration process
would also limit the potential for oﬀ-target eﬀects on the
immune system by a Jak2 inhibitor, eﬀects that however
have not been found relevant in other mouse models [36].
However, it is important to point out that β-thalassemia
major and β-thalassemia intermedia patients who develop
splenomegaly require regular blood transfusions and often
undergo splenectomy. It is appealing to speculate that β-
thalassemia intermedia patients aﬀected by splenomegaly
could be treated temporarily with Jak2 inhibitors so as
to reduce the spleen size and, in the presence of blood
transfusions, to prevent further anemia. This suggests that
even patients aﬀected by β-thalassemia major, who develop
splenomegaly and EMH, may beneﬁt from administration
of Jak2 inhibitors (Melchiori et al., in preparation). In these
settings, the use of Jak2 inhibitors would be expected to
limit or reduce splenomegaly, thereby preventing or delaying
the need for splenectomy and indirectly improving the
management of anemia and iron overload by reducing the
rate of blood transfusions. In conclusion, the use of Jak2
inhibitors for β-thalassemia might be desirable, but it would
require a careful optimization noting the potential for oﬀ-
target immune suppression, as well as the anemia that would
be expected from continuous Jak2 inhibition.
2.3. Iron Overload as a Consequence of Ineﬀective Ery-
thropoiesis. Erythropoiesis and iron metabolism are closely
linked processes. The large majority of iron in our body is
utilized by the erythropoietic system to generate functionally
active hemoglobin molecules, which are harbored in the
RBC. It is estimated that 1800mg of iron in our body are
present in RBCs, 300mg in the bone marrow, and 600mg
in the reticuloendothelial macrophages of the spleen [37],
accounting for more than 60% of total body iron. This
massive utilization of iron by the erythropoietic system
requires the presence of ﬁnely tuned regulatory systems
that allow storage, mobilization, and traﬃco fi r o nw h i l e
preventing toxicity due to highly reactive iron ions. It
is also important to remember that our body lacks an
eﬃcient means of iron excretion. Therefore, its regulation
occurs primarily at the site of absorption in duodenal4 Advances in Hematology
Normal erythropoiesis
Progenitor erythroid cells
pJak2
RBC
RBC Retics
A new model for ineﬀective erythropoiesis
β-thalassemia major
(th3/th3)
β-thalassemia
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Figure 1: In normal erythropoiesis, physiological levels of EPO induce the phosphorylation of Jak2 in normal erythroid progenitors and
sustain the diﬀerentiation to mature RBC (top of the ﬁgure). In β-thalassemia, the high levels of EPO induce an uncontrolled proliferation
of erythroid precursors, with a higher number of cells associated with the phosphorylated form of Jak2. In β-thalassemia intermedia, where
a certain amount of β-globin is still synthesized, there is a high production of reticulocytes that eventually mature in RBC. In β-thalassemia
major, where there is a complete lack of β-globin, the orythroid progenitors continue to proliferate and fail to mature into reticulocytes and
RBC or undergo apoptosis.
Hamp
JAK2
inhibitors
Ineﬀective
erythropoiesis
Iron
overload
Splenomegaly
Figure 2: Diﬀerent approaches to target IE in β-thalassemia. The
administration of hepcidin would allow to decrease the iron over-
loadinorganssuchtheliverandheartandtoredistributetheironto
hematopoietic organs, allowing a more eﬃcient erythropoiesis and
therefore a decrease in splenomegaly. The administration of Jak2
inhibitors would induce a decrease in the ineﬃcient erythropoietic
rate, therefore decreasing spleen size. The reduced erythropoiesis
would have as indirect eﬀect the increase in serum hepcidin, that
in turn would decrease the iron absorption from the gut and the
amelioration of iron overload.
enterocytes. Other important regulatory sites are the liver,
where large quantities of iron can be stored in hepatocytes
andKuppfercells,andthespleen,wheremacrophagesrecycle
iron from senescent RBCs. All three compartments are of
pivotal importance for erythropoiesis since they control the
bioavailability of iron to erythroid progenitors, and all of
them respond to what has been found to be the master
regulatorofironmetabolism,thepeptidehormonehepcidin.
Hepcidin [38, 39] is synthesized mainly in the liver, and
when released into the blood stream, binds to ferroportin,
the major cellular iron exporter expressed at high levels on
the surface of duodenal enterocytes, liver hepatocytes, and
Kuppfercells,andsplenicmacrophages[40–43].Thebinding
of hepcidin to ferroportin induces its internalization and
destruction in the cellular proteasome [44, 45]. Therefore,
the main function of hepcidin is to reduce iron absorption
from enterocytes, and to limit iron export and traﬃcking
from hepatocytes and splenic macrophages. The action of
hepcidin is critical in conditions of iron overload, when too
much iron is potentially bioavailable and a drastic reduction
in its absorption and mobilization is required. Hepcidin
expression is strictly regulated, with multiple pathways that
r e s p o n dt oi r o ns t o r a g e( s t o r a g er e g u l a t o r )[ 46], hypoxia
(hypoxia regulator) [47, 48], inﬂammation (inﬂammatory
regulator) [49–52], and erythropoiesis (erythroid regulator)
[51, 53, 54]. All these systems interact with one another
resulting in a very complex and ﬁnely tuned regulation of
hepcidin expression. Since the intimate relationship between
hepcidin and erythropoiesis exists, it is predictable that
pathologies that involve alteration in the erythropoietic rate,
also involve alterations of iron metabolism and hepcidin
expression. In β-thalassemia, the process of IE is accompa-
nied by a massive iron overload, due to an increased rate
of iron absorption by the gastrointestinal (GI) tract and
to frequent blood transfusions. In this setting, two major
systems would contribute to hepcidin expression, the “stores
regulator” and the “erythroid regulator”. Due to the high
levels of total body iron, the store regulator should actAdvances in Hematology 5
by increasing hepcidin expression thereby avoiding further
iron absorption. On the other hand, the erythroid regulator
would decrease hepcidin expression in an attempt to com-
pensate for anemia due to IE. Our recent study in mouse
models of β-thalassemia intermedia (th3/+) and major
(th3/th3) showed that the erythroid regulator does dictate
the pattern of iron absorption and distribution relative to
the degree of IE (Gardenghi et al., [4]). In th3/+ mice, iron
overload and the degree of IE gradually become more severe
as the animals age. Gardenghi and colleagues demonstrated
how dysregulation of iron absorption in young th3/+ mice
is due mainly to a dramatic decrease of hepcidin expression
in the liver. However, as iron overload progressively increases
in older animals, hepcidin is upregulated, while ferroportin
expression is increased in the GI tract in order to maintain
high levels of iron absorption to compensate for the anemia
in IE. In th3/th3 mice, where IE is more pronounced, the
increased iron absorbed was not found in hematopoietic
organs such as the spleen and bone marrow, but rather in the
liver and other nonhematopoietic organs [4]. This suggests
that that iron is not utilized by erythroid progenitors, as
would be expected according to the model of IE described
above where erythroid progenitors display an increased
proliferative activity but a decreased diﬀerentiation rate,
resulting in a limited synthesis of hemoglobin and therefore
limited iron uptake. Instead, in th3/+ animals where the
degree of IE is lower and there is a substantial eﬀective
erythropoiesis, an increased iron content is found in the
spleen and Kupﬀer cells of the liver [4]. This leads to the
conclusion that the erythroid regulator overrides the store
regulator in th3/th3 mice, resulting in low levels of hepcidin
expression and further increasing the iron concentration in
the liver. In contrast, in states of relatively mild anemia, iron
absorption would be lower and the erythroid organs, spleen
and bone marrow, would utilize part of the absorbed iron,
as is observed in th3/+ animals. The idea that not all the
iron absorbed in β-thalassemia is utilized for erythropoiesis
has been conﬁrmed by our recent data (Gardenghi et al.,
submitted) in th3/+ animals kept on a low iron diet.
These animals show a lower iron content compared to
counterparts fed a regular diet, but do not display a decrease
in hemoglobin levels, suggesting again that an excessive
amount of iron is absorbed in β-thalassemia but is not
utilized for the erythropoietic process.
2.4. Control of Hepcidin Expression by the Erythroid Regulator.
New research data hints at the mechanisms by which the
erythroid compartment controls hepcidin expression. In β-
thalassemia, several factors have been identiﬁed and studied
as candidate hepcidin regulatory proteins including growth
diﬀerentiation factor 15 (GDF15) [55], and human twisted
gastrulation factor (TWSG1) [56]. Both of these two factors
are members of the TGFbeta superfamily, which controls
proliferation, diﬀerentiation, and apoptosis in numerous
cells, and are secreted by erythroid precursors. TWSG1
gene expression occurs early during erythroblast maturation
contrasting with the more sustained increase in GDF15
expression in more mature hemoglobinized erythroblasts.
GDF15, which is elevated in the sera of patients with
β-thalassemia,hastheabilitytodownregulatetheexpression
of hepcidin in vitro, although the mechanism is still unclear.
In fact sera from these patients also suppressed hepcidin
expression, albeit to a lesser degree, after immunoprecipi-
tation of GDF15 [55]. Therefore, GDF15 may play a role
in hepcidin regulation when erythroid precursors undergo
cell death as occurs in the IE observed in β-thalassemia
and refractory anemia with ring sideroblasts (RARS) [57].
TWSG1 has been shown to inhibit the upregulation of
hepcidin by bone morphogenic proteins 2 and 4 (BMP2,
BMP4), mediated by Smad phosphorylation, in human
hepatocytes but was not BMP-mediated in murine hepa-
tocytes [56]. Tanno and colleagues proposed that TWSG1
might act with GDF15 to dysregulate iron homeostasis in
β-thalassemia. These represent new and exciting ﬁndings
that can lead to novel discoveries and clinical applications.
These factors will likely result in additional studies leading to
the potential characterization of novel pathways controlling
hepcidin production, have the potential to be utilized as
prognostic markers, and lead to novel clinically applicable
therapy in the future.
2.5. New Therapeutic Approaches to Limit Iron Absorption.
The strong feedback of increased erythropoietic rate which
suppresses hepcidin raises an important question about
whether agents that limit IE, such as Jak2 inhibitors, could
act indirectly as inducers of hepcidin expression. Our recent
data on th3/+ and transfused th3/th3 mice treated with a
Jak2 inhibitor suggest that this might be the case. Animals
treated with the drug showed increased levels of hepcidin
in the liver compared to animals treated with a placebo.
Moreimportantly,thelevelsofhepcidinnegativelycorrelated
with the spleen weight in these animals, suggesting a strong
connection between spleen weight, erythropoietic activity,
and hepcidin expression in β-thalassemia. Jak2 inhibitors
could have a more direct eﬀe c to ni r o nm e t a b o l i s m .T h i s
is suggested by a recent study that shows how expression of
transferrin receptor 1 (TfR1) on erythroid cells depends on
Jak2-Stat5 signaling [58]. Perhaps the use of Jak2 inhibitors
could reduce the expression of TfR1 on erythroid cells, limit-
ing iron uptake and potentially reducing the toxicity induced
by free iron ions. In this scenario, the therapeutic treatment
of β-thalassemiapatients with Jak2 inhibitors could be useful
as it would target the two major complications of this
pathology, IE with its related splenomegaly and the massive
iron overload. Therefore, not only the erythroid cells would
beneﬁt from the lower iron load, but also liver parenchimal
cells and cells in other tissues (i.e., heart) that are damaged
in iron overload conditions. Another therapeutic approach
to decrease iron overload might be to increase the expression
of hepcidin in thalassemic patients. Our recent study (Gar-
denghi et al., submitted) showed thatincreasing the hepcidin
levels in th3/+ mice both by administration of exogenous
synthetic hepcidin and by overexpressing hepcidin reduces
organ iron overload resulting in a marked beneﬁcial eﬀect
on hepatosplenomegaly and erythropoiesis. This reveals a
potential role for hepcidin or hepcidin agonists in the
treatment of abnormal iron absorption in β-thalassemia and
other related disorders.6 Advances in Hematology
3. Summary
Recent studies shed new light on the molecular mechanisms
that underlie IE in β-thalassemia. These ﬁndings suggest
that Jak2 plays a role in the onset of IE and splenomegaly,
and show how the use of Jak2 inhibitors to limit these
processes could open exciting new therapeutic options for
thalassemic patients. The large body of work on hepcidin
is starting to reveal evidence of what has long been held
to be true, the existence of an “erythroid regulator”. The
discovery of erythroid factors that regulate hepcidin produc-
tion suggests possible new therapeutic targets to decrease
iron overload. Furthermore, the evidence that exogenous
hepcidin administration can ameliorate organ iron load
without aﬀecting anemia opens a new therapeutic ﬁeld
for hepcidin agonists/mimetics involving the treatment of
diﬀerent kinds of hemochromatosis (Figure 2).
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